Investor Centre

Servatus is an Australian biotechnology company with global leadership in live
biotherapeutic drug development to treat autoimmune diseases

Corporate Snapshot

Company Overview

Servatus is an Australian biotechnology company with global leadership in live bio therapeutic drug development to treat autoimmune diseases.

Phase 2 clinical trials to create pharmaceutical grade live bio therapeutic agents to treat rheumatoid arthritis are in progress and initial trial results have been received.

Stock Overview

Servatus is an unlisted public company. The share register is held with Registry Direct.

Milestone Objectives

Completion of the Australian extension of the rheumatoid arthritis clinical trial
The rapid commercial expansion of our Biomiq consumer business
Continued investment in the completion of candidate selection for our protein therapeutics program.

Learn more about Servatus >

Live Biotherapeutics

Servatus has isolated and characterised select microbial strains and
undertaken extensive pre-clinical investigations to develop highly
defined medicines that target autoimmune, inflammatory
and chronic conditions.

A key project is the development of pharmaceutical-grade live
biotherapeutics agents derived from micro-organisms predominantly
of bacterial origin.
‍
Phase 2A human clinical trials have confirmed the clinical utility of these medicines for the treatment of rheumotoid arthritis, with the aim to advance safe and effective treatments

Engineered Proteins

As current drugs reach their limit in providing long-term efficacy and
safety for patients, harnessing new modes of action provides the
greatest opportunity to advance medical therapies for the future.
‍
Servatus' research is directed at improving the specific characteristics
of select proteins to provide safe, effective treatments for immune
mediated inflammatory diseases. Servatus targets key features of
the protein to improve its clinical efficacy and to complement existing
drug therapies.
‍
Servatus has engineered a modified protein selected on its inherent
immune-modulating ability, with anticipated improvements in clinical
efficacy and commercial delivery.

Market Size & Opportunity

The fastest growing segment of the biological pharmaceutical market is the
treatment of chronic inflammatory conditions. These conditions include diseases of ageing, which are increasing as the population grows older. This trend is evident in affluent Western societies and in high-growth economies in Asia.
‍
Chronic inflammation can be caused by autoimmune diseases. Autoimmune
diseases affect millions of people globally. The market is large in terms of patients requiring treatment, and potential to generate revenue.

Although the current use of anti-tumour necrosis factor (TNF) biologics for a
selection of autoimmune diseases is well established, there are still large resources devoted to finding other drugs to treat rheumatoid arthritis and other autoimmune diseases.

Anti-tumour necrosis factor drugs are also coming off patent, and there are
indications that generic antibodies are being developed in the US, Europe and China to enter this market. New drugs under patent will have a significantly longer life of premium pricing compared to existing biological treatments.
‍
In 2023, three of the top 10 drugs globally were for the treatment of autoimmune
diseases, specifically rheumatoid arthritis, psoriasis and Inflammatory Bowel Disease (IBD). These three drugs alone represented approximately $US36 billion in global sales.

biomiq

biomiq is a carefully curated product portfolio designed to nourish and enhance the human microbiome.

biomiq gives you back control of your health, helping to cultivate the ideal environment to support optimal digestion, immune health, good skin, and overall wellbeing.

Our Research Facility

Our own research and production facility means that Servatus is able to oversee all aspects of the research development and production pipeline and ensure that our live biotherapeutic drug candidates (LBPs) are made to our high-standard and specifications, and removes the logistical uncertainty often associated with outsourcing manufacturing.